AstraZeneca PLC (AZN)

127.25
0.00(0.00%)
  • Volume:
    1,078
  • Bid/Ask:
    127.25/127.35
  • Day's Range:
    126.50 - 128.05

AZN Overview

Prev. Close
127.25
Day's Range
126.5-128.05
Revenue
-
Open
127.2
52 wk Range
95.25-136.95
EPS
-
Volume
1,078
Market Cap
197.43B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
7,294
P/E Ratio
-
Beta
-
1-Year Change
28.41%
Shares Outstanding
1,549,516,692
Next Earnings Date
-
What is your sentiment on AstraZeneca?
or
Market is currently closed. Voting is open during market hours.

AstraZeneca PLC News

AstraZeneca PLC Analysis

AstraZeneca PLC Company Profile

AstraZeneca PLC Company Profile

Employees
83100
  • Type:Equity
  • Market:Germany
  • ISIN:GB0009895292
  • WKN:886455

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company’s marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellBuyStrong Buy
Technical IndicatorsSellStrong SellStrong SellStrong BuyStrong Buy
SummarySellStrong SellStrong SellStrong BuyStrong Buy
  • Pfizer and Moderna fell big time in share prices, while Astra kept it’s stable 9ish. How?
    1
    • money to get
      0
    • hello please help you
      1
    • Attila, AZ & Pfizer are pharmaceutical companies that makes medicines. They are not just providers of vaccines. At present, and for the foreseeable future, the AZ science is much stronger than that of Pfizer, and similar to Merck, which is another pharmaceutical company that has grown materially this year. I am long on AZ and Merck.
      0
  • An attractive PRE-IPO called SpectrumX based in England plans to launch by November and i'm very hopeful of this particular investment. Clinical trials for their Covid-19 respiratory treatment are now in phase 2 of development which will be a game changer once hospitals get their hands on it. This will not be factored into the company valuation when listed. So if the trials are successful the market value will rocket. Thats why im seriously excited about this IPO and i don't usually go near PRE IPO's.
    4
    • how's it doing today
      0
    • how's it doing today
      0
  • 50
    0
    • *50000
      0
  • 19970410🌍 10000%
    0
    • Most of vunerable demographic now vaccinated. Will younger people accept the jab or will potential health concerns outweigh the potential benefits. I'm short AstraZeneca
      5
      • net short positions available on the PNC Borsa app
        0
        • Above 7500 to 9750 soon these weeks bullish sentiments business development infrastructure expenditures stimulus package cause its stance growth economics of scales
          2
          • you are nostetadamoos
            1
        • may be buy or sell the stock but be very cautious before being vaccinated : some serious cases in Europe especially with young to intermediate people
          11
          • GP GAPYes Im chief nurse teacher in a very big hospital. Not specialised in vaccine but i know a little bit about heath. And im a pro vaccine. But the rule we were givenby health autorities  was : Astra not for people under 55.
            1
          • Thanks for the advise.
            0
          • Jenny Goughlike dada
            0
        • This is moving now....at last! US approval coming.
          1
          • The cause behind the suspected vaccine side effects has been found. This is the opinion of a Norwegian expert group that examined the three healthcare employees who were admitted to hospital after being vaccinated with Astra Zeneca's vaccine. The vaccine triggered a strong immune reaction in the people. - I see no other reason than that it is the vaccine that triggers it, says the chief physician and professor Pål Andre Holme to VG. Sell off coming
            5
            • I guess that puts this Professor at odds with all the others looking at the data then.   Strange they were all healthcare employees.
              0
            • u shorting?
              1